Skip to content
Spiritual Quotes – Lifestyle
Author:
BioNxt Solutions Inc.
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
June 15, 2026
BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
May 19, 2026
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
April 14, 2026
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
April 7, 2026
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
March 30, 2026
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
March 17, 2026